All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

CLLSCellectis S.A.
35Calm
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Running, no new patientsPhase 1/245 patientsMain results: Sep 16, 2026
CNSYCerenome
0Calm
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Running, no new patientsPhase 1/255 patientsMain results: Apr 2027
GSKGlaxoSmithKline
0Calm
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Signing up patientsPhase 1/254 patientsMain results: Mar 24, 2028
MRKMerck Sharp & Dohme LLC
2Calm
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Signing up patientsPhase 3680 patientsMain results: May 16, 2033
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Signing up patientsPhase 1/2170 patientsMain results: Nov 29, 2030
ALXOALX Oncology Inc.
4Calm
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Signing up patientsPhase 2120 patientsMain results: Dec 2027
NVSNovartis Pharmaceuticals
0Calm
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Running, no new patientsPhase 1/246 patientsMain results: Sep 3, 2027
GSKGlaxoSmithKline
0Calm
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Running, no new patientsPhase 2351 patientsMain results: Oct 26, 2026
CMPXCompass Therapeutics
0Calm
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
Signing up patientsPhase 258 patientsMain results: Sep 2028
AZNAstraZeneca
0Calm
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Running, no new patientsPhase 3724 patientsMain results: Oct 31, 2028
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Signing up patientsPhase 3876 patientsMain results: Aug 22, 2034
MRKMerck Sharp & Dohme LLC
2Calm
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Running, no new patientsPhase 3686 patientsMain results: Jun 15, 2028
NVSNovartis Pharmaceuticals
0Calm
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Signing up patientsPhase 2272 patientsMain results: Aug 21, 2029
AZNAstraZeneca
0Calm
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Running, no new patientsPhase 3510 patientsMain results: Jun 7, 2016
NVSNovartis Pharmaceuticals
0Calm
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Running, no new patientsPhase 223 patientsMain results: Nov 6, 2026
BMYBristol-Myers Squibb
3Calm
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Signing up patientsPhase 31,000 patientsMain results: Jul 30, 2030
SNYSanofi
0Calm
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Running, no new patientsPhase 3943 patientsMain results: Mar 24, 2028
INBXInhibrx Biosciences, Inc
0Calm
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Signing up patientsPhase 1/2340 patientsMain results: Jul 2033
CMPXCompass Therapeutics
0Calm
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Running, no new patientsPhase 2/3168 patientsMain results: Aug 31, 2027
RVMDRevolution Medicines, Inc.
0Calm
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Signing up patientsPhase 3400 patientsMain results: Mar 2029
REGNRegeneron Pharmaceuticals
5Calm
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Running, no new patientsPhase 1/2148 patientsMain results: Nov 2, 2035
AMGNAmgen
12Calm
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Running, no new patientsPhase 3563 patientsMain results: Apr 2, 2030
BMYBristol-Myers Squibb
3Calm
Pan Tumor Rollover Study
Signing up patientsPhase 21,500 patientsMain results: Aug 25, 2029
MRKMerck Sharp & Dohme LLC
2Calm
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Signing up patientsPhase 2372 patientsMain results: Dec 31, 2029
RVMDRevolution Medicines, Inc.
0Calm
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Signing up patientsPhase 3670 patientsMain results: Dec 30, 2028